Antithrombotic and anticoagulant therapy for atrial fibrillation

Area of Science:

• Cardiology
• Vascular Medicine
• Pharmacology

Background:

• Atrial fibrillation (AF) significantly elevates the risk of stroke and thromboembolic events.
• Effective antithrombotic prophylaxis is crucial for managing AF patients.
• Oral anticoagulation (OAC) is a primary strategy for stroke prevention in AF.

Purpose of the Study:

• To review the role of antithrombotic prophylaxis in atrial fibrillation.
• To compare the efficacy and safety of different antithrombotic strategies.
• To emphasize the importance of individualized risk assessment in AF management.

Main Methods:

• Review of current clinical guidelines and evidence on antithrombotic therapy in AF.
• Comparative analysis of oral anticoagulants (VKAs and non-VKAs) versus antiplatelet agents.
• Discussion of stroke and bleeding risk assessment tools.

Main Results:

• Oral anticoagulation (OAC), including vitamin K antagonists (VKAs) and non-VKAs, is superior to antiplatelet therapy for stroke prevention in AF.
• Antiplatelet drugs (aspirin, clopidogrel) show comparable bleeding risk to OAC but are less effective in preventing thromboembolic events.
• Individualized risk assessment for stroke and bleeding is essential for optimal OAC selection and management.

Conclusions:

• OAC is the preferred antithrombotic strategy for most patients with atrial fibrillation.
• Risk stratification is mandatory to guide the choice of antithrombotic therapy and minimize adverse events.
• Antiplatelet agents are not recommended as a substitute for OAC in AF for stroke prevention.